Coherus BioSciences (FRA:8C5) ROCE % : -99.90% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Coherus BioSciences's annualized ROCE % for the quarter that ended in Dec. 2024 was -99.90%.

Coherus BioSciences ROCE % Historical Data

The historical data trend for Coherus BioSciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences ROCE % Chart

Coherus BioSciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

30.82

-45.52

-62.93

-60.83

24.66

Coherus BioSciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-85.03	174.66	-13.96	-10.08	-99.90

Coherus BioSciences ROCE % Calculation

Coherus BioSciences's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	53.16	/	( ( (577.347 - 304.234)	+	(428.349 - 270.247) )	/ 2 )
	=	53.16	/	( (273.113	+	158.102)	/ 2 )
	=	53.16	/	215.6075
	=	24.66 %

Coherus BioSciences's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-173.236	/	( ( (455.005 - 266.305)	+	(428.349 - 270.247) )	/ 2 )
	=	-173.236	/	( ( 188.7	+	158.102 )	/ 2 )
	=	-173.236	/	173.401
	=	-99.90 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Coherus BioSciences (FRA:8C5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Coherus BioSciences ROCE % Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Coherus BioSciences Headlines

No Headlines